北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant
作者: Yan Chenhua; Xu Lanping; Liu Daihong; Chen Huan; Wang Yu; Liu Kaiyan; Huang Xiaojun
关键词: allogeneic hematopoietic stem cell transplantation ; haploidentical ; graft-versus-host disease ; modified donor lymphocyte infusion ; graft-versus-leukemia effects
刊名: CHINESE MEDICAL JOURNAL
发表日期: 2014-10-20
DOI: 10.3760/cma.j.issn.0366-6999.20141481
卷: 127, 期:20, 页:3602-3609
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Medicine, General & Internal
研究领域[WOS]: General & Internal Medicine
关键词[WOS]: STEM-CELL TRANSPLANTATION ; BONE-MARROW-TRANSPLANTATION ; ACUTE MYELOID-LEUKEMIA ; HEMATOLOGICAL MALIGNANCIES ; LEUKOCYTE INFUSIONS ; RISK-FACTORS ; RELAPSE
英文摘要:

Background In haploidentical hematopoietic stem cell transplantation (HSCT), the duration of graft-versus-host disease (GVHD) prophylaxis after modified donor lymphocyte infusion (DLI) was the only risk factor of DLI-associated grades 3-4 acute GVHD. However, the successful application of modified DLI depended not only on the reduction of severe GVHD, but also on the preservation of graft-versus-leukemia (GVL) effect. Therefore, this study was performed to compare the impact of prophylaxis for 6-8 weeks and prophylaxis for <6 weeks on GVL effect after modified DLI in haploidentical HSCT.

Methods A total of 103 consecutive patients developing hematological relapse or minimal residual disease (MRD)-positive status after haploidentical HSCT and receiving modified DLI were investigated retrospectively. Fifty-two patients received prophylaxis for 6-8 weeks after modified DLI; the remaining 51 patients received prophylaxis for <6 weeks.

Results First, compared with prophylaxis for <6 weeks, prophylaxis for 6-8 weeks reduced incidence of relapse in total patients (26.6% vs. 69.0%, P<0.001). Besides, prophylaxis for 6-8 weeks also reduced incidence of relapse in 54 patients developing hematological relapse post-transplant (P=0.018) and in 49 patients developing MRD-positive status post-transplant (P<0.001). Second, prophylaxis for 6-8 weeks reduced incidence of acute GVHD (P<0.05), reduced the therapeutic application of immunosuppressive agents (P=0.019), but increased the incidence of chronic GVHD (P<0.05). Third, prophylaxis for 6-8 weeks improved overall survival and disease-free survival in total patients, as well as in patients developing hematological relapse post-transplant and in patients developing MRD-positive status post-transplant (P<0.05).

Conclusions In haploidentical HSCT, prophylaxis for 6-8 weeks after modified DLI does not reduce GVL effect, but reduces the incidence of DLI,associated acute GVHD compared with prophylaxis for <6 weeks. This strategy will probably improve the safety and efficacy of modified DLI further.

语种: 英语
WOS记录号: WOS:000344724100016
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/51666
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Inst Hematol, Dept Hematol,Peoples Hosp, Beijing 100044, Peoples R China

Recommended Citation:
Yan Chenhua,Xu Lanping,Liu Daihong,et al. Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant[J]. CHINESE MEDICAL JOURNAL,2014,127(20):3602-3609.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Yan Chenhua]'s Articles
[Xu Lanping]'s Articles
[Liu Daihong]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Yan Chenhua]‘s Articles
[Xu Lanping]‘s Articles
[Liu Daihong]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace